Acute Heart Failure (AHF) Therapeutics

Acute Heart Failure (AHF) Therapeutics

Global Acute Heart Failure (AHF) Therapeutics Market to Reach US$2.9 Billion by 2030

The global market for Acute Heart Failure (AHF) Therapeutics estimated at US$748.7 Million in the year 2023, is expected to reach US$2.9 Billion by 2030, growing at a CAGR of 21.3% over the analysis period 2023-2030. Cardiac Glycosides, one of the segments analyzed in the report, is expected to record a 21.8% CAGR and reach US$762.4 Million by the end of the analysis period. Growth in the B-Blockers segment is estimated at 24.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$200.4 Million While China is Forecast to Grow at 30.1% CAGR

The Acute Heart Failure (AHF) Therapeutics market in the U.S. is estimated at US$200.4 Million in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$841.2 Million by the year 2030 trailing a CAGR of 30.1% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 15.6% and 17.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 16.5% CAGR.

ACUTE HEART FAILURE (AHF) THERAPEUTICS - KEY TRENDS AND DRIVERS

Acute heart failure (AHF) is a critical condition marked by the sudden onset of heart failure symptoms or the worsening of existing heart conditions, posing severe health risks due to the heart`s inability to pump sufficient blood. This medical emergency, involving systemic congestion and potential organ dysfunction, requires immediate and effective management strategies to ensure patient survival and maintain quality of life. The complexity of AHF`s pathophysiology, which can stem from a variety of cardiac abnormalities, complicates its treatment and highlights the necessity of differentiated approaches for its two main forms: de novo heart failure and acutely decompensated heart failure. While the former demands a comprehensive diagnosis to identify the underlying cardiac issue in patients with no prior history of heart disease, the latter focuses on managing the abrupt deterioration of an existing chronic condition.

Treatment protocols for AHF emphasize managing symptoms and addressing the root causes of the heart`s reduced functionality. Initial strategies typically include non-invasive ventilation and rapid administration of diuretics to alleviate fluid overload, which is a common complication of AHF. Alongside these, other therapeutic interventions such as vasodilators are used to reduce cardiac load in patients with stable blood pressure, while inotropic support is reserved for severe cases to maintain hemodynamic stability. Additionally, the use of anticoagulants is recommended to prevent thromboembolic events in susceptible patients, underscoring the importance of a balanced approach that considers both efficacy and safety. Moreover, an early post-discharge follow-up is crucial for optimizing long-term management and reducing the chances of hospital readmission, reflecting a proactive approach to patient care that extends beyond the initial treatment phase.

The landscape of AHF therapeutics is evolving, driven by several growth factors including technological advancements in diagnostics, increased adoption of remote patient monitoring, and greater patient awareness and education about heart failure. Innovations in cardiac imaging and biomarker diagnostics enhance the precision of AHF detection and monitoring, facilitating timely and personalized treatment interventions. Additionally, the integration of artificial intelligence and machine learning in healthcare systems is revolutionizing AHF therapy by improving the accuracy of patient assessments and optimizing treatment protocols. The development of novel pharmaceuticals and expansion of treatment modalities, such as gene therapy and biologics, are broadening the spectrum of therapeutic options available, appealing to a diverse patient population and healthcare providers. Moreover, changes in the regulatory and reimbursement landscape are encouraging the adoption of advanced, albeit often expensive, treatments. As AHF continues to be a major cause of hospital readmission and mortality, these factors collectively contribute to the dynamic advancement and adoption of new therapeutic strategies, shaping the future of AHF management.

Select Competitors (Total 93 Featured) -

• Bayer AG
• Bristol-Myers Squibb Company
• Cardiorentis AG
• CVie Therapeutics Limited
• Cytokinetics, Inc.
• Merck & Co., Inc.
• Novartis AG
• Orion Corporation
• PhaseBio Pharmaceuticals, Inc.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.